Super‐stable homogeneous embolic agents advance the treatment of hepatocellular carcinoma

Peng, Yujia; Cheng, Hongwei; Liang, Hui; Zhang, Yang; Liu, Gang

doi:10.1002/ird3.22

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For moderatestage HCC, transcatheter arterial chemoembolization (TACE) shows therapeutic efficiency. More recently, some novel embolic materials and technologies have been employed, especially the superstable homogeneous iodinated formulation technology (SHIFT), showing long-term stability and favorable pharmaceutical value (2)(3)(4)(5). However, over 50% of patients with HCC are diagnosed at advanced stages and therefore not suitable for surgical or locoregional therapies (6).…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

Li,

Hu,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Background and aimsSystemic combinations have recently brought significant therapeutic benefits for advanced hepatocellular carcinoma (aHCC). To design the most effective combination regimens, a systematic review (PROSPERO ID: CRD42022321949) was conducted to evaluate the efficacy and safety of systemic combinations on aHCC.MethodsWe retrieved all the studies from PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and China National Knowledge Infrastructure (CNKI) using the Medical Subject Headings (MeSH) terms until December 21, 2022. The effect indicators (hazard ratio [HR], relative risk [RR], and median) were pooled by a fixed- or random-effects model. A subgroup analysis was conducted according to types and specific therapies.ResultsIn total, 88 eligible studies were selected from 7249 potential records. Each kind of combination treatment (chemotherapy plus chemotherapy, targeted plus immune checkpoint inhibitor (ICI) therapy, targeted plus chemotherapy, and targeted plus targeted therapy) had a better objective response rate (ORR) in patients with aHCC, compared to the monotherapy mostly with sorafenib (RR: 1.57 [1.44–1.71]; I2 = 30%). Of those, targeted plus ICI therapy showed better therapeutic efficiency in overall survival (median: 15.02 [12.67–17.38]), progression-free survival (median: 7.08 [6.42–7.74]), and ORR (RR: 1.81 [1.55–2.13]), compared to the monotherapy. Specifically, Atezo plus Beva showed all those benefits. Our pooled result showed all the combinations had increased ≥3 Grade treatment-related adverse events (TrAEs), with an RR of 1.25 [95% CI: 1.15–1.36], compared to the monotherapy.ConclusionThe systemic combinations, especially targeted plus ICI therapy, including Atezo plus Beva, significantly improve clinical outcomes but increase side effects in patients with aHCC. Future trials should concentrate on improvement in therapeutic efficiency and reduction of toxicity of targeted plus ICI therapy.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42022321949.

show abstract

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

Li,

Hu,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Living Cell‐Derived Intelligent Nanobots for Precision Oncotherapy

Zhou,

Li,

Liu

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

The progress of precision oncology medicine is always limited by the tumor off‐targeting, the drug side effects, and the treatment inefficiency due to the complex and ever‐changing tumor microenvironment. Living cells, such as blood cells and immune cells, exhibit natural tumor tropism, controllable physicochemical modification, and excellent biocompatibility, which provide an advantageous pathway for innovative and efficient tumor suppression. Armed with nanoengineering techniques, artificial living cells harness their inherent biological properties to precisely identify and eradicate tumors, demonstrating broad biological application prospects and great transformational potential in personalized cancer therapy. Here, the recent advances of living cell‐based bionanobots including platelets, red blood cells, neutrophil, macrophage, and CAR‐T cells for cancer precision therapy and immune regulation are summarized, and the efficient anti‐tumor strategies for engineering living cell nanorobots to overcome complex biological barriers and immune suppression are also outlined (e.g., immunotherapy, sonodynamic therapy, chemo/radiotherapy, and phototherapy). In addition, the study discusses the advantages, limitations, and current challenges of artificial living cell‐based drug delivery systems, and provide perspectives on the future development of living cell‐mediated precision tumor nanomedicine.

show abstract

Supercritical Fluids: An Innovative Strategy for Drug Development

Liu,

Liang,

Peng

et al. 2024

Bioengineering

View full text Add to dashboard Cite

Nanotechnology plays a pivotal role in the biomedical field, especially in the synthesis and regulation of drug particle size. Reducing drug particles to the micron or nanometer scale can enhance bioavailability. Supercritical fluid technology, as a green drug development strategy, is expected to resolve the challenges of thermal degradation, uneven particle size, and organic solvent residue faced by traditional methods such as milling and crystallization. This paper provides an insight into the application of super-stable homogeneous intermix formulating technology (SHIFT) and super-table pure-nanomedicine formulation technology (SPFT) developed based on supercritical fluids for drug dispersion and micronization. These technologies significantly enhance the solubility and permeability of hydrophobic drugs by controlling the particle size and morphology, and the modified drugs show excellent therapeutic efficacy in the treatment of hepatocellular carcinoma, pathological scarring, and corneal neovascularization, and their performance and efficacy are highlighted when administered through multiple routes of administration. Overall, supercritical fluids have opened a green and efficient pathway for clinical drug development, which is expected to reduce side effects and enhance therapeutic efficacy.

show abstract

Super‐stable homogeneous embolic agents advance the treatment of hepatocellular carcinoma

Cited by 3 publications

References 30 publications

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis

Living Cell‐Derived Intelligent Nanobots for Precision Oncotherapy

Supercritical Fluids: An Innovative Strategy for Drug Development

Contact Info

Product

Resources

About